Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)

Samsung Bioepis revealed promising results for SB27, a biosimilar intended to replicate Keytruda (Pembrolizumab), with both Phase 1 and Phase 3 studies showing promising outcomes in terms of pharmacokinetic equivalence and equivalent objective response rates. These preliminary successes could pave the way for a more affordable alternative to the high-cost cancer immunotherapy. The implications are significant, potentially offering patients more accessible treatment options while putting pressure on established biotech giants to innovate further. The completion of these studies by 2026 could further enhance the biosimilar market landscape.